Zai Lab Ltd. logo

Zai Lab Ltd. (ZLAB)

Market Closed
24 Jul, 20:00
NASDAQ (NMS) NASDAQ (NMS)
$
37. 77
+0.4
+1.07%
$
4.13B Market Cap
- P/E Ratio
0% Div Yield
674,872 Volume
-3.45 Eps
$ 37.37
Previous Close
Day Range
37.24 37.96
Year Range
16.01 44.34
Want to track ZLAB and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 13 days
Wall Street Analysts Believe Zai Lab Limited (ZLAB) Could Rally 95.6%: Here's is How to Trade

Wall Street Analysts Believe Zai Lab Limited (ZLAB) Could Rally 95.6%: Here's is How to Trade

The consensus price target hints at a 95.6% upside potential for Zai Lab Limited (ZLAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks | 5 months ago
Zai Lab: Rapidly Improving Outlook Bodes Well For The Future

Zai Lab: Rapidly Improving Outlook Bodes Well For The Future

Zai Lab Limited is transitioning from a "Hold" to a "Buy" rating due to rapid revenue growth and upcoming potential approvals. ZLAB's strategy involves in-licensing U.S.-approved drugs for the Chinese market, with key products like Zejula, Qinlock, Nuzyra, Vyvgart, and Optune driving revenue. Despite high costs, ZLAB's consistent quarterly revenue growth and a strong cash position indicate a promising future.

Seekingalpha | 7 months ago
Zai Lab Limited (ZLAB) Upgraded to Buy: What Does It Mean for the Stock?

Zai Lab Limited (ZLAB) Upgraded to Buy: What Does It Mean for the Stock?

Zai Lab Limited (ZLAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks | 7 months ago
Compared to Estimates, Zai Lab Limited (ZLAB) Q3 Earnings: A Look at Key Metrics

Compared to Estimates, Zai Lab Limited (ZLAB) Q3 Earnings: A Look at Key Metrics

The headline numbers for Zai Lab Limited (ZLAB) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks | 8 months ago
Zai Lab Limited (ZLAB) Q3 2024 Earnings Call Transcript

Zai Lab Limited (ZLAB) Q3 2024 Earnings Call Transcript

Zai Lab Limited (NASDAQ:ZLAB ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Christine Chiou - Senior Vice President, Investor Relations Samantha Du - Founder, Chairperson and Chief Executive Officer Josh Smiley - President and Chief Operating Officer Rafael Amado – President, Head of Global Research and Development Yajing Chen - Chief Financial Officer Conference Call Participants Michael Yee - Jefferies Yigal Nochomovitz - Citigroup Operator Hello, ladies and gentlemen. Thank you for standing by.

Seekingalpha | 8 months ago
Zai Lab Limited (ZLAB) Moves 14.7% Higher: Will This Strength Last?

Zai Lab Limited (ZLAB) Moves 14.7% Higher: Will This Strength Last?

Zai Lab Limited (ZLAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks | 9 months ago
Zai Lab Limited (ZLAB) Surges 11.1%: Is This an Indication of Further Gains?

Zai Lab Limited (ZLAB) Surges 11.1%: Is This an Indication of Further Gains?

Zai Lab Limited (ZLAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks | 10 months ago
Zai Lab's Growth Strategy And China's Policy Reforms Set Path For Profitability By 2025

Zai Lab's Growth Strategy And China's Policy Reforms Set Path For Profitability By 2025

Zai Lab Limited leverages global partnerships to commercialize approved therapies in China, focusing on oncology, autoimmune, infectious, and neurological conditions. ZLAB's leading products include VYVGART, AUGTYRO (Repotrectinib), and XACDURO, with VYVGART contributing significantly to Q2 2024 revenues. ZLAB is also developing wholly-owned IP, including ZL-1310 and ZL-1218, which could extend its global footprint beyond China.

Seekingalpha | 10 months ago
Trade of the Day: Zai Lab (ZLAB) Stock Is a Possible Hidden Gem

Trade of the Day: Zai Lab (ZLAB) Stock Is a Possible Hidden Gem

It's not often that a genuine hidden-gem candidate appears in the market. But that label might apply to Chinese biotechnology firm Zai Lab (NASDAQ: ZLAB ).

Investorplace | 0 year ago